Download PDF
Horm Metab Res 1995; 27(1): 31-34
DOI: 10.1055/s-2007-979902
Originals Clinical

© Georg Thieme Verlag Stuttgart · New York

Effect of Antibodies to Calcitonin on the Pharmacokinetics and the Pharmacodynamics of the Hormone

F. Tagliaro1 , R. Dorizzi2 , G. Luisetto3
  • 1Institute of Forensic Medicine, University of Verona, Verona
  • 2Clinical Chemistry Laboratory, Hospital of Legnago, Legnago
  • 3Department of Endocrinology, University of Padova, Padova, Italy
Further Information

Publication History

1994

1994

Publication Date:
23 April 2007 (online)

Also available at
  PDF Download  Permissions and Reprints

Abstract

Calcitonin pharmacokinetics and pharmacodynamics were studied in two groups of patients with postmenopausal osteoporosis, who, treated for one year with intranasal Asu1,7-eel calcitonin (eCT), had (Ab+) and had not (Ab-) developed a specific immune response to the drug. The treatment consisted of daily intranasal administrations of eCT (80 IU/die) with 1 g supplemental calcium. Eight women who had developed specific antibodies and 5 who had not, were given 50 IU of CT i.m., in order to assess the pharmacokinetics and pharmacodynamics of the drug. The rise of serum levels of the hormone was significantly greater in Ab+ than in Ab- patients. At the end of the study, no significant differences in mineral bone loss between the two groups were found. In conclusion, the presence of antibodies to eCT does not represent a negative event in the therapy of osteoporosis, but significantly affects the pharmacokinetics of the drug.

Key words

Asu1,7-eel Calcitonin - Antibodies - Calcitonins - Osteoporosis - Intranasal Therapy